BIOMAT Database Logo BIOMAT Database Logo

Development of potent and proteolytically stable human neuromedin U receptor agonists. 2018

An De Prins, and Charlotte Martin, and Yannick Van Wanseele, and Louise Julie Skov, and Csaba Tömböly, and Dirk Tourwé, and Vicky Caveliers, and Ann Van Eeckhaut, and Birgitte Holst, and Mette Marie Rosenkilde, and Ilse Smolders, and Steven Ballet
Research Group of Organic Chemistry, Departments of Chemistry and Bioengineering Sciences, Vrije Universiteit Brussel, Pleinlaan 2, 1050, Brussels, Belgium; Department of Pharmaceutical Chemistry, Drug Analysis and Drug Information, Center for Neurosciences (C4N), Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.

Neuromedin U (NMU) is a highly conserved endogenous peptide that is involved in a wide range of physiological processes such as regulation of feeding behavior, the stress response and nociception. The major limitation to use NMU as a therapeutic is its short half-life. Here, we describe the development of a set of novel NMU-analogs based on NMU-8, by introducing unnatural amino acids into the native sequence. This approach shows that it is possible to generate molecules with increased potency and improved plasma stability without major changes of the peptidic nature or the introduction of large conjugates. When compared to the native NMU-8 peptide, compounds 16, 18 and 20 have potent agonist activity and affinity for both NMU receptors. Selectivity towards NMUR1 was observed when the Phe residue in position 4 was modified, whereas higher potencies at NMUR2 were found when substitutions of the Pro residue in position 6 were executed. To study the effect of the modifications on the proteolytic stability of the molecules, an in vitro stability assay in human plasma at 37 °C was performed. All analyzed analogs possessed an increased resistance against enzymatic degradation in human plasma resulting in half-lifes from 4 min for NMU-8, up to more than 23 h for compound 42.

UI MeSH Term Description Entries
D009479 Neuropeptides Peptides released by NEURONS as intercellular messengers. Many neuropeptides are also hormones released by non-neuronal cells. Neuropeptide
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D059748 Proteolysis Cleavage of proteins into smaller peptides or amino acids either by PROTEASES or non-enzymatically (e.g., Hydrolysis). It does not include Protein Processing, Post-Translational. Protein Degradation,Protein Digestion,Degradation, Protein,Degradations, Protein,Digestion, Protein,Digestions, Protein,Protein Degradations,Protein Digestions,Proteolyses
D017981 Receptors, Neurotransmitter Cell surface receptors that bind signalling molecules released by neurons and convert these signals into intracellular changes influencing the behavior of cells. Neurotransmitter is used here in its most general sense, including not only messengers that act to regulate ion channels, but also those which act on second messenger systems and those which may act at a distance from their release sites. Included are receptors for neuromodulators, neuroregulators, neuromediators, and neurohumors, whether or not located at synapses. Neurohumor Receptors,Neuromediator Receptors,Neuromodulator Receptors,Neuroregulator Receptors,Receptors, Neurohumor,Receptors, Synaptic,Synaptic Receptor,Synaptic Receptors,Neuromediator Receptor,Neuromodulator Receptor,Neuroregulator Receptor,Neurotransmitter Receptor,Receptors, Neuromediators,Receptors, Neuromodulators,Receptors, Neuroregulators,Receptors, Neurotransmitters,Neuromediators Receptors,Neuromodulators Receptors,Neuroregulators Receptors,Neurotransmitter Receptors,Neurotransmitters Receptors,Receptor, Neuromediator,Receptor, Neuromodulator,Receptor, Neuroregulator,Receptor, Neurotransmitter,Receptor, Synaptic,Receptors, Neuromediator,Receptors, Neuromodulator,Receptors, Neuroregulator

Related Publications

An De Prins, and Charlotte Martin, and Yannick Van Wanseele, and Louise Julie Skov, and Csaba Tömböly, and Dirk Tourwé, and Vicky Caveliers, and Ann Van Eeckhaut, and Birgitte Holst, and Mette Marie Rosenkilde, and Ilse Smolders, and Steven Ballet
Discovery of potent hexapeptide agonists to human neuromedin u receptor 1 and identification of their serum metabolites.
March 2015, ACS medicinal chemistry letters,
An De Prins, and Charlotte Martin, and Yannick Van Wanseele, and Louise Julie Skov, and Csaba Tömböly, and Dirk Tourwé, and Vicky Caveliers, and Ann Van Eeckhaut, and Birgitte Holst, and Mette Marie Rosenkilde, and Ilse Smolders, and Steven Ballet
A potent neuromedin U receptor 2-selective alkylated peptide.
October 2017, Bioorganic & medicinal chemistry letters,
An De Prins, and Charlotte Martin, and Yannick Van Wanseele, and Louise Julie Skov, and Csaba Tömböly, and Dirk Tourwé, and Vicky Caveliers, and Ann Van Eeckhaut, and Birgitte Holst, and Mette Marie Rosenkilde, and Ilse Smolders, and Steven Ballet
Unanticipated Characteristics of a Selective, Potent Neuromedin-U Receptor 2 Agonist.
August 2022, ACS bio & med chem Au,
An De Prins, and Charlotte Martin, and Yannick Van Wanseele, and Louise Julie Skov, and Csaba Tömböly, and Dirk Tourwé, and Vicky Caveliers, and Ann Van Eeckhaut, and Birgitte Holst, and Mette Marie Rosenkilde, and Ilse Smolders, and Steven Ballet
Design of Potent and Proteolytically Stable Biaryl-Stapled GLP-1R/GIPR Peptide Dual Agonists.
May 2022, ACS chemical biology,
An De Prins, and Charlotte Martin, and Yannick Van Wanseele, and Louise Julie Skov, and Csaba Tömböly, and Dirk Tourwé, and Vicky Caveliers, and Ann Van Eeckhaut, and Birgitte Holst, and Mette Marie Rosenkilde, and Ilse Smolders, and Steven Ballet
Design and synthesis of peptidic partial agonists of human neuromedin U receptor 1 with enhanced serum stability.
September 2020, Bioorganic & medicinal chemistry letters,
An De Prins, and Charlotte Martin, and Yannick Van Wanseele, and Louise Julie Skov, and Csaba Tömböly, and Dirk Tourwé, and Vicky Caveliers, and Ann Van Eeckhaut, and Birgitte Holst, and Mette Marie Rosenkilde, and Ilse Smolders, and Steven Ballet
A chemically stable peptide agonist to neuromedin U receptor type 2.
May 2020, Bioorganic & medicinal chemistry,
An De Prins, and Charlotte Martin, and Yannick Van Wanseele, and Louise Julie Skov, and Csaba Tömböly, and Dirk Tourwé, and Vicky Caveliers, and Ann Van Eeckhaut, and Birgitte Holst, and Mette Marie Rosenkilde, and Ilse Smolders, and Steven Ballet
Design of Potent and Proteolytically Stable Oxyntomodulin Analogs.
February 2016, ACS chemical biology,
An De Prins, and Charlotte Martin, and Yannick Van Wanseele, and Louise Julie Skov, and Csaba Tömböly, and Dirk Tourwé, and Vicky Caveliers, and Ann Van Eeckhaut, and Birgitte Holst, and Mette Marie Rosenkilde, and Ilse Smolders, and Steven Ballet
Development of potent and selective human A3 adenosine receptor agonists.
January 2005, Nucleic acids symposium series (2004),
An De Prins, and Charlotte Martin, and Yannick Van Wanseele, and Louise Julie Skov, and Csaba Tömböly, and Dirk Tourwé, and Vicky Caveliers, and Ann Van Eeckhaut, and Birgitte Holst, and Mette Marie Rosenkilde, and Ilse Smolders, and Steven Ballet
Discovery of selective hexapeptide agonists to human neuromedin U receptors types 1 and 2.
August 2014, Journal of medicinal chemistry,
An De Prins, and Charlotte Martin, and Yannick Van Wanseele, and Louise Julie Skov, and Csaba Tömböly, and Dirk Tourwé, and Vicky Caveliers, and Ann Van Eeckhaut, and Birgitte Holst, and Mette Marie Rosenkilde, and Ilse Smolders, and Steven Ballet
Potent Body Weight-Lowering Effect of a Neuromedin U Receptor 2-selective PEGylated Peptide.
July 2017, Journal of medicinal chemistry,
Copied contents to your clipboard!